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proteinT cell immunoglobulin andmucin domain 1 and 4 (TIM-1 and -4) proteins serve as phosphatidylserine receptors
to engulf apoptotic cells. Here we show that human TIM-1 and TIM-4 proteins are targets of A Disintegrin And
Metalloprotease (ADAM)-mediated ectodomain shedding resulting in soluble forms of TIM-1 and TIM-4. We
identiﬁed ADAM10 and ADAM17 as major sheddases of TIM-1 and TIM-4 as shown by protease-speciﬁc in-
hibitors, the ADAM10 prodomain, siRNA and ADAM10/ADAM17 deﬁcient murine embryonic ﬁbroblasts
(MEFs). TIM-1 and TIM-4 lacking the intracellular domain were efﬁciently cleaved after ionomycin- and
PMA-treatment, indicating that the intracellular domain was not necessary for ectodomain shedding. Soluble
TIM-1 and -4were able to bind to phosphatidylserine, suggesting that soluble TIM-1 and -4might act as negative
regulators of cellular TIM-1 and -4. In summary, we describe TIM-1 and TIM-4 as novel targets for ADAM10- and
ADAM17-mediated ectodomain shedding.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The T cell immunoglobulin and mucin domain (TIM) gene family
plays important roles in immune responses, including transplant toler-
ance, autoimmunity, regulation of allergy and asthma, and response to
viral infections [1,2]. There are eight TIM (pseudo)-genes in mouse, but
only three in humans, coding for 4 murine (TIM-1–4) and 3 human
(TIM-1, -3 and -4) TIM proteins, respectively [3]. As all other TIM-
proteins, TIM-1 and TIM-4 are type I cell-surface glycoproteins with an
N-terminal immunoglobulin (Ig)-like domain, a mucin domain with
O-linked and N-linked glycosylation, a single trans-membrane domain,
and a cytoplasmic region with a tyrosine phosphorylation motif [4].
Among the TIM proteins, TIM-1, TIM-3 and TIM-4 are receptors for
phosphatidylserine [5,6], and phosphatidylserine-exposure is a hallmark
of apoptosis leading to engulfment of apoptotic cells.
TIM-1 was previously described as the renal epithelial cell protein
KIM-1. TIM-1 is up-regulated in tubular epithelial cells and undergoes
ectodomain shedding following kidney injury [7,8]. TIM-1 expression
was, however, also found on several immune cells, including activateddium; FBS, fetal bovine serum;
d Molecular Biology II, Medical
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er).
ights reserved.T cells (preferentially Th2 cells) [9], mast cells [10], natural killer cells
[11], dendritic cells [12] and B cells [13]. Inhibition of TIM-1 signaling
improved ischemia reperfusion injury in the liver mediated by reduced
inﬁltration of neutrophils and generation of pro-inﬂammatory cyto-
kines [14]. Treatment of mice with anti-TIM-1 monoclonal antibodies
(mAbs) led to increased survival, less tubular necrosis and less local
inﬂammation after kidney ischemia reperfusion [15]. Moreover, anti-
TIM-1 mAbs co-stimulated T cell proliferation, enhanced Th2 cytokine
production and prevented thedevelopment of induced peripheral toler-
ance inmice [16]. TIM-1was suggested as amarker for regulatory B cells
inﬂuencing their IL-10 production [17,18]. TIM-1 is an important sus-
ceptibility gene of allergy and asthma [19].
TIM-4 is expressed on antigen presenting cells (APCs), including
macrophages and dendritic cells [20–22]. TIM-4 is a ligand of TIM-1
[23]. It is still under debate, whether TIM proteins directly interact
with each other or whether there is an indirect association of two TIM
proteins binding to separate phosphatidylserine molecules on the sur-
face of a cell membrane [24]. No interaction was detected between
soluble TIM-1-Fc and soluble TIM-4-Fc fusion proteins [13]. T cell prolif-
eration was enhanced by soluble TIM-4-Fc and anti-CD3/anti-CD28
mAbs [25]. On the other hand, inhibition of naive T cell proliferation
by soluble TIM-4-Fc was independent of TIM-1 [26]. Moreover, soluble
TIM-1 is a biomarker for acute kidney injury and renal cell carcinoma
in humans [27–29].
Soluble protein ectodomains are generated by ectodomain shedding
or limited proteolysis of trans-membrane proteins resulting in protein
276 O. Schweigert et al. / Biochimica et Biophysica Acta 1843 (2014) 275–287down-regulation at the cell surface. The soluble protein ectodomains
have agonistic and/or antagonistic properties. In some cases, ectodomain
cleavage leads to the generation of an intracellular fragment, which
induced intracellular signaling, as shown for Notch [30]. Members of A
Disintegrin And Metalloprotease (ADAM) gene family are ectodomain
shedding proteinases. Among them, ADAM10 and ADAM17 are the
major sheddases with more than 100 substrates [31]. There is, however,
extensive overlap and compensation between ADAM proteases for
several substrates [32,33]. Different stimuli including phorbol ester
(phorbol-12-myristate-13-acetate (PMA)), ionomycin, ATP, ligands
of G-protein coupled receptors (GPCR), bacterial toxins, bacterial
metalloproteases and induction of apoptosis activate ADAM10-
and/or ADAM17-mediated shedding of trans-membrane proteins
[31]. Recently, it has been shown that TIM-1 undergoes ectodomain
cleavage mediated by MMP3 [34]. Here, we provide evidence that
TIM-1 and TIM-4 are novel substrates of ADAM10 and ADAM17 and
that soluble TIM-1 and TIM-4 can bind to phosphatidylserine.
2. Material and methods
2.1. Cells and reagents
HEK293 cells were obtained from the American Type Culture Collec-
tion (Rockville, MD/Manassas, VA, USA). Murine embryonic ﬁbroblasts
(MEFs) deﬁcient for ADAM10, ADAM17 and ADAM10/ADAM17were de-
scribed previously [32,35–37]. HEK293 and MEF cells were grown in
DMEM high glucose culture medium supplemented with 10% fetal calf
serum (FCS) at 37 °C with 5% CO2 in a water-saturated atmosphere. The
human kidney carcinoma cell line 769-P was obtained from LGC Stan-
dards (Wesel, Germany). 769-P cells were cultured in RPMI 1640 Medi-
um (PAA Laboratories, Coelbe, Germany) supplemented with 10% fetal
calf serum (FCS) at 37 °C with 5% CO2 in a water-saturated atmosphere.
Phorbol-12-myristate-13-acetate (PMA), 2′(3′)-O-(4-benzoylbenzoyl)
adenosine 5′-triphosphate triethylammonium salt (BzATP), ionomycin
and 1,2-Diacyl-sn-glycero-3-phospho-L-serine solution (PS, #P6641)
were purchased from Sigma-Aldrich (Deisenhofen, Germany).
The broad-spectrum metalloprotease-inhibitor marimastat (MA),
GI254023X (GI, ADAM10-selective) and GW280264X (GW, ADAM10
and ADAM17-selective) have been described [38]. The recombinant
murine ADAM10 pro-domain (A10pro) was described previously [39].
siRNA oligonucleotides were supplied from the ON-TARGET plus collec-
tion (ThermoScientiﬁc, Dreieich, Germany) andwere designed to target
human ADAM10 (L-004503-00-0005) or human ADAM17 (L-003453-
00-0005). A non-targeting pool (D-001810-10-05) was used as a nega-
tive control. Basement Membrane Matrix (BD Matrigel, # 356230) was
purchased from BD Bioscience (Heidelberg, Germany).
2.2. Antibodies
Mousemonoclonal anti-TIM-1 IgG2b antibody (BBCR, sc-80359)was
obtained from Santa Cruz Biotechnology Inc. (Heidelberg, Germany).
The antibodies mouse anti-hADAM10-PE IgG1 (clone SHM14), mouse
anti-hTIM-1-PE IgG1 (clone 1D12), mouse anti-hTIM4-PE IgG1 (clone
9 F4) andmouse IgG1-PE isotype control (clone MOPC-21) were pur-
chased from Biolegend (London, UK). The antibodies for ADAM17
staining, mouse anti-hADAM17-FITC, isotype control IgG1-FITC and
biotinylated anti-TIM-1 antibody (1750-TM) were obtained from
R&D Systems (Abingdon, UK).
2.3. Construction of expression plasmids
The plasmid Puc57-hTIM-4 (synthesized by GENEART, Munich,
Germany) was digested with AﬂII and NotI and subcloned into the ex-
pression vector pcDNA3.1(+) containing the signal peptide from the
murine immunoglobulin kappa-chain, an N-terminal FLAG-tag and a
C-terminal 6xHis tag. For creation of hTIM-1 without FLAG-tag, mRNAof 769-P cells was isolated and cDNA synthesized via reverse transcrip-
tion. For the ampliﬁcation of hTIM-1 CDS the primers 5′h1-full-CDS-for
(5′-GATCCTTAAGATGCATCCTCAAGTGGTCATC-3′) and 3′h1-full-CDS-
rev (5′-GATCGCGGCCGCTTAGTCCGTGGCATAAAGAC-3′) were used.
The ampliﬁed insert was digested with EcoRI and NotI and cloned into
the expression vector pcDNA3.1(+).
For obtaining the alkaline phosphatase (AP) cDNA, the plasmid
pCRscript-AP-TGFα (Stratagene, Waldbronn, Germany) was digested
with HindIII and the AP portion was subcloned into the pcDNA3.1-
hTIM-4 plasmid. For generation of AP-hTIM1, TIM-1 was subcloned
into the pcDNA3.1-AP-hTIM-4 plasmid via AﬂII and NotI.
The deletions of the sequence coding for the mucin stalk region
of the human TIM-1 (ranging from phenylalanine 282 to threonine
289 (Δ282-289 (FLEHSLL))) were performed by SOE (splicing by
overlapping-extension)-PCR, which preserved the original signal
peptide coding sequence of the human TIM-1. For the deletion of
F282 to T289 the primers 5′hTIM1-Δ1for (5′-AACAATCAAACTCAACTG
ACGGCCAATACCACTAAAGGAATC-3′) and 3′hTIM1-Δ1rev (5′-GGTATT
GGCCGTCAGTTGAGTTTGATTGTTATTCCAAAGGCC-3′) were used. The
ampliﬁed insert was digested with EcoRI and NotI and cloned into the
expression vector pcDNA3.1(+). For generation of AP-TIM-1 Δ282-
289, the ampliﬁed insert TIM-1 Δ282-289 was subcloned into the
pcDNA3.1-AP-hTIM-4 plasmid via AﬂII and NotI. The resulting plasmids
were named TIM-1 Δ282-289 and AP-TIM-1 Δ282-289.
The deletions of the sequence coding for the mucin stalk region of
the human TIM-4 (from methionine 304 to glutamine 314 (Δ304–
314), from threonine 294 to methionine 304 (Δ294–304) and aspartic
acid 283 to threonine 294 (Δ283–294))were performedby SOE (splicing
by overlapping-extension)-PCR,which preserved the original signal pep-
tide coding sequence of the human TIM-4. For the deletion fromM304 to
Q314 the primers 5′AP-hTIM-4-Δ1for (5′-CAGATGGAGCCCATCTCCCAAC
TACTG-3′) and 3′AP-hTIM-4-Δ1rev (5′-GAGATGGGCTCCATCTGTCCTGTT
TTTG-3′) were used. For the deletion from T294 to M304 the primers 5′
AP-hTIM-4-Δ2for (5′-CCTGAGCATGGAATACCCATGTCAATGAAG-3′) and
3′AP-hTIM-4-Δ2rev (5′-GGGTATTCCATGCTCAGGAACTGCTGTATC-3′)
were used. For the deletion from D283 to T294 the primers 5′AP-hTIM-
4-Δ3for (5′-CCTGGAGCATCTAAAACAGGACAGATGGATGG-3′) and 3′
AP-hTIM-4-Δ3rev (5′-CTGTCCTGTTTTAGATGCTCCAGGCTGAGGAG-3′)
were used. The resulting plasmids were named AP-TIM-4 Δ304–314,
AP-TIM-4 Δ294–304 and AP-TIM-4 Δ284–294, respectively. For the
generation of TIM-4-mutants without AP-tag, the inserts were digested
with AﬂII and NotI and subcloned into the expression vector
pcDNA3.1(+). The constructs were named TIM-4 Δ304–314, TIM-4
Δ294–304 and TIM-4 Δ284–294.
For the deletion of the entire intracellular domain (TIM1-ΔICD: from
alanine 316 to aspartic acid 364 and TIM4-ΔICD: from arginine 337 to
leucine 378) the primers 5′AP-hTIM-1for (5′-GACTCTTAAGTCTGTAAA
GGTTGGTGGAGAGG-3′), 3′AP-hTIM-1-ΔICDrev (5′-GATCGCGGCCGC
AATGATGACACCCAAAAGAGC-3′), 5′AP-hTIM-4for (5′-GACTCTTAAG
GAGACTGTTGTGACGGAGGTTTTG-3′) and 3′AP-hTIM-4-ΔICDrev
(5′-GATCGCGGCCGCTCTCAGGAGAAACGCCACAAAC-3′) were used.
The resulting PCR products were cloned into pcDNA3.1-AP-hTIM-4
plasmid via AﬂII and NotI. The plasmids were named AP-hTIM-1-ΔICD
and AP-hTIM-4-ΔICD.
2.4. Anti-TIM-1 and TIM-4 antibody generation
The pcDNA3.1-hTIM-4 plasmid was used as a template to amplify
the IgV-domain of the human TIM-4 with the primers 5′IgVhTIM-4-
NdeI-for (5′-GCTCCATATGTCAGAGACTGTTGTGACGGAGG-3′) and 3′
IgVhTIM-4-NotI-rev (5′-GATCGCGGCCGCTGAGGCTCTCTGTAGATTC-
3′). The resulting PCR product was cloned into the bacterial expression
vector pET-23a(+) (Novagen, Darmstadt, Germany) using NdeI and
NotI restriction sites. The pET23a-hTIM-4-IgV was transformed into
Escherichia coli BL21. Transformed cellswere grown at 37 °C in Lysogeny
Broth (LB) medium supplemented with ampicillin (100 μg/ml), and
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37 °C for 4 h. The bacterial culture was then harvested by centrifugation
and lysed using soniﬁcation. The resulting inclusion bodies containing
the hTIM-4-IgV protein were denaturated using 6 M GuHCl in 50 mM
Tris buffer, pH 8. The renaturation of hTIM-4-IgV peptidewas performed
via rapid dilution in refolding buffer containing 0.1 M Tris–HCl, pH 8.5,
400 mM L-arginine, 2 mM EDTA, 4 mM reduced glutathione and
0.4 mM oxidized glutathione. The refolded hTIM-4-IgV protein was
concentrated and the buffer was changed by a Nap-10 column
(GE Healthcare, Munich, Germany) to PBS. The hTIM-4-IgV protein
was puriﬁed via Superdex75 16/60 column (GE Healthcare, Munich,
Germany) equilibrated in PBS. The monomeric peptide was collected
and concentrated to 1 mg/ml. C57BL/6 mouse (Charles River, Koeln,
Germany) was initially immunized intraperitoneally (i.p.) with 100 μg
of puriﬁed hTIM-4-IgV domain in 60 μl phosphate buffer saline (PBS)
emulsiﬁedwith 40 μl of Gerbu adjuvantMM(GerbuBiotech., Heidelberg,
Germany). The mice were boosted i.p. on days 14 and 21 with 50 μg of
puriﬁed TIM-4 protein emulsiﬁed with 20% of the adjuvant. The last
two doses (50 μg hTIM-4-IgV in PBS) were administered on days 28
and 29 without adjuvant, while fusion was performed on day 30. Spleen
cells from immunized animals were collected and fused with Ag8.653
myeloma cells using polyethylene glycol 1500 (Roche Diagnostics,
Mannheim, Germany). The fused cells were cultured in selection
medium (HAT, Sigma-Aldrich, Deisenhofen, Germany) for 10 days
and screened by ELISA for anti-hTIM-4-IgV antibodies.
2.5. Puriﬁcation of mAbs
The hybridomas were cultivated in serum-free medium (RPMI 1460
hybridoma express plus, PAA Laboratories, Coelbe, Germany) supple-
mented with β-mercaptoethanol, sodium pyruvate and antibiotics
(Penicillin/Streptomycin, PAA Laboratories, Coelbe, Germany) and incu-
bated with 5% CO2 at 37 °C. After two weeks, the supernatants were
pooled and ﬁltered through 0.22 μm ﬁlters and concentrated 10-fold.
The puriﬁcation was performed using HiTrap Protein G HP
(GE Healthcare, Munich, Germany) according to themanufacturer's
procedure. Brieﬂy, the column was equilibrated with binding buffer
(20 mM phosphate, pH 7.4) followed by loading of the sample. After
washingwith binding buffer, themAbswere eluted with 0.1 M glycine,
pH 2.7 and directly neutralized with 1 M Tris–HCl, pH 9.0. The buffer
was changed by Nap-10 column (GE Healthcare, Munich, Germany) to
PBS and the anti-TIM-4 antibodies (clones T27-2 and T27-3) were con-
centrated to 1 mg/ml. The isotype of T27-2 (IgG2a, κ) was determined
by using the Rapid ELISA Mouse mAb Isotyping Kit (Thermo Scientiﬁc,
Dreieich, Germany). For the use in ELISA assays, the T27-2 antibody
was conjugated to biotin via EZ-Link Sulfo-NHS-Biotinylation Kit
(#21425, Thermo Scientiﬁc Pierce, Dreieich, Germany).
2.6. Transfection of cells
HEK293 cells and murine embryonic ﬁbroblasts (MEFs) were
transiently transfected using TurboFect (Thermo Scientiﬁc, Dreieich,
Germany). For generation of stable HEK293-hTIM-4 cells, HEK293 cells
were transfected with pcDNA3.1-hTIM-4 plasmid, which contained the
neomycin drug resistance gene, and selected by using 0.8 μg/ml G418
(PAA Laboratories, Coelbe, Germany).
2.7. Transfection with siRNA against ADAM10 and ADAM17
To knockdown ADAM10 and/or ADAM17 expression at the mRNA
level, 5 × 105/well 769-P or HEK293-hTIM4 cells were seeded onto a
6 well plate a day before transfection. Cells were transfected with
1 μM siRNA and 5.6 μl of DharmaFECT 1/well according to the
manufacturer's procedure (Thermo Scientiﬁc, Dreieich, Germany). The
non-target siRNAs were used as control. For double knockdown, 1 μM
of each siRNAwas applied. After 24 h in culture, the cellswere detachedfrom cell culture plates with Trypsin/EDTA. Cells from each of the 6
wells were separated into two 12 wells and cultured for additional
48 h.2.8. Shedding assays of TIM-1 and TIM-4
HEK293 cellswere stimulated 48 hpost transfection. For stimulation
with BzATP, HEK293 cells were additionally cotransfected with plasmid
pcDNA6-hP2X7R [40]. To analyze shedding of endogenous TIM-1,
1 × 105 769-P cells were seeded 48 h before stimulation. For BzATP
treatment, 769-P cells were transiently transfected with pcDNA6-
hP2X7R. For detection of shed TIM-1 and TIM-4, cells were washed
with sterile phosphate-buffered saline (PBS). If not stated otherwise,
the ADAM10-inhibitor GI (3 μM), the combined ADAM10/ADAM17-
inhibitor GW (3 μM), or the speciﬁc ADAM10-inhibitor proA10
(10–20 μM) were added 30 min before stimulation with BzATP
(500 μM), ionomycin (2.5–5 μM) or PMA (100 nM) in serum-free
DMEM or RPMI medium (0.5–0.6 ml per 6 well). Conditioned media
from transiently transfected cells were cleared by centrifugation
(5 min at 16,000 g) and 50 μl was used for Western blotting. Condi-
tioned media from 769-P cells were concentrated by SpeedVac® Plus
SC110A (Thermo Scientiﬁc, Dreieich, Germany) from 250 μl to a ﬁnal
volume of 50 μl. To generate lysates, cells were scraped from the surface
of a ﬂask with a cell scraper, pelleted and lysed in lysis buffer (50 mM
HEPES, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% IGEPAL (NP-40), 1%
SDS and 0.5% sodium deoxycholate, supplemented with complete
protease inhibitor cocktail tablets (Roche Diagnostics, Mannheim,
Germany)).2.9. Western blotting
Samples (lysates and concentrated supernatants) were mixed with
reducing loading buffer and heated for 5 min at 95 °C. Proteins were
separated by SDS-PAGE on 4–10% polyacrylamide gels and transferred
to a polyvinylidene diﬂuoride membrane (GE Healthcare, Munich,
Germany). The membrane was blocked with 5% skimmed milk in
Tris-buffered saline with Tween-20 (TBS-T; 10 mM Tris–HCl,
pH 7.6, 150 mM NaCl and 0.5% Tween 20) and probed with primary
antibodies as indicated at 4 °C overnight. After washing with TBS-T,
the membranes were incubated with the appropriate secondary anti-
bodies conjugated to horseradish peroxidase (HRP; Thermo Scientiﬁc
Pierce, Perbio, Bonn, Germany), and protein bands were visualized
with the ECL detection system (GE Healthcare, Munich, Germany)
according to themanufacturer's instructions.Western blots were quan-
tiﬁed using ImageJ software.2.10. Alkaline phosphatase shedding assay
For photometric quantiﬁcation of AP-TIM-1 and AP-TIM-4 shedding,
transiently transfected HEK293 cells were stimulated as indicated. To
measure the alkaline phosphatase activity, conditioned medium and
1:10 diluted lysates (50 μl per well) were mixed with 50 μl of reaction
solution (0.1 M glycine, 1 mMMgCl2, 1 mM ZnCl2 containing 1 mg/ml
4-nitrophenyl phosphate disodium salt hexahydrate (Sigma-Aldrich,
Deisenhofen, Germany)). The alkaline phosphatase removes the
phosphate group that forms the p-nitrophenyl phosphate (pNNP),
which is then deprotonated under alkaline conditions to produce
p-nitrophenolate that has a strong absorption at 405 nm. Absorbance
was read at 405 nm (microplate reader rainbow, Tecan, Crailsheim,
Germany) and refers to the alkaline phosphatase (AP)-activity. The
AP-activity of soluble AP-TIM-1 and AP-TIM-4 was calculated as a
ratio of AP-activity in the supernatant relative to the total AP-activity
(sum of the supernatant- and the lysate-AP-activity).
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Cell surface staining of TIM-1 and TIM-4 was performed using anti-
TIM-1-PE (R&D Systems, Minneapolis, MN, USA), anti-TIM-1-PE, anti-
TIM-4-PE (Biolegend, London, UK) and the relevant isotype controls
according to the manufacturer's instructions. Staining of human TIM-4
was performed using mouse monoclonal anti-hTIM-4-T27-2 or
corresponding isotype control mouse IgG2a (Biolegend, London, UK)
and the secondary antibody anti-mouse-APC (Dianova, Hamburg,
Germany).
The cells were analyzed by ﬂow cytometry (BD Biosciences, Heidel-
berg, Germany— FACSCanto and FACSDIVA software). To detect surface
expression of hTIM-1 and mutants thereof, transiently transfected
HEK293 cells were washed with FACS buffer (PBS, 0.25% bovine serum
albumin (BSA)) and incubated at 1 × 106 cells/100 μl FACS buffer con-
taining 1 μg anti-human TIM-1-PE or PE-mouse IgG1, κ isotype control
(Biolegend, London, UK) in FACS buffer for 60 min at 4 °C. To detect
cell surface expression of hTIM-4 and mutants thereof, transiently
transfected HEK293 cells were washed with FACS buffer and incubated
at 1 × 106 cells/100 μl FACS buffer containing 1 μg T27-2 antibody or
IgG2a isotype control (Biolegend, London, UK) for 60 min at 4 °C. To de-
tect the cell surface expression of hTIM-4 on M-CSF-derived macro-
phages, cells were washed with FACS buffer, blocked with 25% human
serum and incubated at 1 × 106 cells/100 μl FACS buffer containing
2 μg T27-2 antibody or IgG2a isotype control (Biolegend, London, UK)
for 60 min at 4 °C. Cells were washed twice with FACS buffer,
re-suspended and incubated for additional 60 min with the secondary
antibody anti-mouse-APC. To verify the cell surface expression of
ADAM10 and ADAM17 in 769-P cells after transfection with siRNA,
cells were washed with FACS buffer and incubated at 1 × 106cells/
100 μl FACS buffer containing 1 μg anti-hADAM10-PE/isotype control
IgG1-PE (Biolegend, London, UK) or 0.75 μg anti-hADAM17-FITC/isotype
control IgG1-FITC (R&D Systems, Abingdon, UK). After staining, cells
were washed twice with FACS buffer, re-suspended and analyzed by
ﬂow cytometry (BD Biosciences, Heidelberg, Germany — FACSCanto
and FACS DIVA software).
2.12. Phosphatidylserine/-cholin—ELISA
The binding of soluble TIM-1 and TIM-4 proteins to phospha-
tidylserine was veriﬁed via PS–ELISA [21]. In brief, 10 μg/ml of
phosphatidylserine solution or phosphatidylcholine (Sigma-Aldrich,
Deisenhofen, Germany), diluted in methanol, was added to 96-well
plate (100 μl per well). The plate was air-dried for 1 h and blocked for
2 h with 1% BSA in PBS. 100 μl of supernatants, containing soluble
TIM-1 or TIM-4, were added and incubated for 2 h at room tempera-
ture. The wells were extensively washed to remove the unbound pro-
teins with PBS-T (PBS containing 0.05% Tween-20). The detection of
bound proteins was veriﬁed using biotinylated anti-TIM-1 (#1750-
TM, R&D Systems, Abingdon, UK) or biotinylated T27-2 antibodies and
peroxidase-conjugated streptavidin (R&D Systems, Abingdon, UK). To
detect the peroxidase activity, BM Blue POD Substrate (Roche Diagnos-
tics, Mannheim, Germany) was added. The reaction was stopped with
1 M H2SO4 and the absorbance was measured by 450 nm inmicroplate
reader (SLT Rainbow, Tecan, Maennedorf, Switzerland).
2.13. Generation of human M-CSF-derived macrophages
Human PBMCs were isolated from peripheral blood using lympho-
cyte separationmediumHistopaque 1077 (Sigma-Aldrich, Deisenhofen,
Germany) density gradient centrifugation. CD14+monocytes were fur-
ther puriﬁed from PBMCs by negative selection using Monocyte Isola-
tion Kit II with column puriﬁcation according to the manufacturer's
instructions (Miltenyi Biotec, Bergisch-Gladbach, Germany). The cells
were cultured in RPMI 1640 containing 10% FCS, 100 μg/ml penicillin–
streptomycin, 2 mM L-glutamine, 50 nM β-Mercaptoethanol, 1 mMsodium pyruvate and non-essential amino acids, 100 nM each (PAA,
Cölbe, Germany). To generatemacrophages, 1 × 107 CD14+monocytes
were cultured for 10 days in the presence of 100 ng/ml of M-CSF
(eBioscience, Frankfurt, Germany). After 10 days, differentiated macro-
phageswere detached from cell culture plates with acutase (PAA, Cölbe,
Germany) and 4 × 105 cells were seeded onto 12 wells or 1 × 105 cells
were seeded onto 12 wells on coverslips. After 48–72 hour cultivation,
cells were stimulated with 1 μg/ml LPS for 2 h, 1 μM ionomycin for
30 min, 100 nM PMA for 1 h or with 500 μM BzATP for 30 min.
ADAM10-inhibitor GI (3 μM), combined ADAM10/ADAM17-inhibitor
GW (3 μM) and broad-metalloprotease inhibitor marimastat (3 μM)
were added 30 min before stimulation in serum-free RPMI medium.
For plasmamembrane staining 5 μg/mlWGA-FITC (Vector Laboratories,
Burlingame, CA) was added 10 min before the end of the stimulation.
Following stimulation the macrophages were stained for TIM-4 and
analyzed via FACS-analysis.
2.14. Immunoﬂuorescence microscopy staining for TIM-4
M-CSF-derivedmacrophages on coverslips were ﬁxedwith 4% para-
formaldehyde, blocked with 25% human serum, in some cases perme-
abilized (with 0.25% Triton-X-100 in PBS) and stained for TIM-4 using
T27-2 and secondary anti-mouse-DyLight-649 (Thermo Scientiﬁc
Pierce, Perbio, Bonn, Germany) antibodies. Stained coverslips were em-
bedded in DAPI-Mounting-Medium (Dianova, Hamburg, Germany).
Confocal images were acquired using an IX81 ﬂuorescence microscope
(Olympus, Hamburg, Germany). Image analysis was performed using
Olympus FluoView FV1000 Software (Olympus, Hamburg, Germany).
3. Results
3.1. Shedding of TIM-1 and TIM-4 is mediated by ADAM10 and ADAM17
HEK293 cells were transiently transfected with expression plasmids
coding for TIM-1 or an N-terminally FLAG-tagged TIM-4 variant. Cell
surface expression of TIM-1 and TIM-4 was veriﬁed by ﬂow cytometry
using anti-TIM-1 and anti-TIM-4 mAbs (Fig. 1A). To test whether
TIM-1 and TIM-4 are substrates for ADAM proteases, TIM-1 or TIM-4
expressing HEK293 cells were stimulated with PMA, BzATP or ionomycin
in the absence or presence of the ADAM10-inhibitor GI254023X (GI), the
combined ADAM10/ADAM17-inhibitor GW280264X (GW) or were left
untreated. Ionomycin and BzATP are activators of ADAM10-mediated
ectodomain shedding and PMA is a general activator of ADAM17-
mediated shedding [30]. BzATP- and ionomycin-treatment led to the
release of soluble TIM-1 and TIM-4 into the cell culture supernatant
(Fig. 1B and C). The ADAM10-inhibitor GI inhibited the release of TIM-1
and TIM-4 into the cell culture supernatant after ionomycin- and
BzATP-treatment (Fig. 1B and C). TIM-1 and TIM-4 were also shed after
PMA-treatment. PMA-induced shedding was partially inhibited by
ADAM10-inhibitor GI and almost completely inhibited by the combined
ADAM10/ADAM17-inhibitor GW (Fig. 1B and C). We conclude from
these experiments that ADAM10 and ADAM17 are ectodomain
sheddases of TIM-1 and TIM-4.
Next, HEK293 cells were transfectedwith cDNAs coding for TIM-1 or
TIM-4 and stimulated with ionomycin in the presence or absence of the
ADAM10 prodomain (proA10), which inhibits ADAM10 [39]. ProA10
partially inhibited the ionomycin-induced shedding of TIM-1 (Fig. 1D).
For the inhibition of ionomycin-induced shedding of TIM-4, a higher
concentration of proA10 was needed (Fig. 1E). Moreover, proA10 did
not inhibit the PMA-induced shedding of TIM-1 and TIM-4 (Fig. 1D
and E), although the ADAM10-inhibitor GI partially inhibited PMA-
induced shedding as shown in Fig. 1B and C.
Next, we generated expression plasmids coding for alkaline
phosphatase-TIM-1 and TIM-4 fusion proteins (AP-TIM-1 and AP-
TIM-4) consisting of N-terminal alkaline phosphatase (AP), a FLAG
tag, the TIM-1 or TIM-4 protein and a C-terminally located His-tag.
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Fig. 1. Expression and induced shedding of human TIM-1 and TIM-4. (A) Heterologous expression of the TIM-1 and TIM-4 proteins on the cell surface of HEK293 cells. HEK293 cells were
transfected with expression plasmids for the TIM-1 and TIM-4, immunostained for TIM-1 using anti-TIM-1-PE or TIM-4 using mouse T27-2 primary and secondary anti-mouse-APC
antibodies and analyzed by ﬂow cytometry (isotype control in gray). (B–E) HEK293 cells expressing TIM-1 or TIM-4 were stimulated with BzATP (30 min, 500 μM), ionomycin
(30 min, 5 μM) or PMA (60 min, 100 nM) in presence or absence of ADAM10-inhibitor GI (3 μM), combined ADAM10/ADAM17-inhibitor GW (3 μM) or speciﬁc ADAM10-inhibitor
proA10 (10–20 μM). Lysates and conditioned media were analyzed by Western blotting using mouse anti-TIM-1 or anti-TIM-4 antibodies. Fold change was calculated using ImageJ.
279O. Schweigert et al. / Biochimica et Biophysica Acta 1843 (2014) 275–287Cell surface expression of AP-TIM-1 and AP-TIM-4 was veriﬁed by ﬂow
cytometry (Fig. 2A). AP-TIM-1 or AP-TIM-4 expressing HEK293 cells
were stimulated with PMA or ionomycin in the absence or presence of
the ADAM10-inhibitor GI, the combined ADAM10/ADAM17-inhibitor
GW or were left untreated. As shown in Fig. 2B and C, shedding of AP-
TIM-1 and AP-TIM-4 was induced by BzATP-, ionomycin- and PMA-
treatment. BzATP- and ionomycin-induced shedding was completely
inhibited by the ADAM10-inhibitor GI and the ADAM10/ADAM17-
inhibitor GW. PMA-induced shedding was completely inhibited by
GW. Again the ADAM10-inhibitor GI partially inhibits PMA-induced
shedding of AP-TIM-1 and AP-TIM-4. Results obtained with chemical
inhibitors have to be interpreted with caution, since speciﬁcity might
not be guaranteed at higher concentrations. Even though, we and others
have observed speciﬁc inhibition of ADAM10 andADAM17with 3 μMGI
andGW[38,41], other studies have also beenperformedwith lower con-
centrations (0.2–1 μM) [33,42]. Since PMA was described to speciﬁcally
activate ADAM17 but not ADAM10 [30], we performed dose–response
curves with GI and GW concentrations ranging from 0.2 to 3 μM to
test if the inhibitor concentration of 3 μMwas adequate. As depicted in
Supplemental Fig. 1, ionomycin-induced TIM-1 and TIM-4 shedding
was inhibited at all concentrations of GI and GW in a dose-dependent
manner. Inhibition of PMA-induced shedding was also inhibited at all
concentrations of GW. GI-mediated inhibition of PMA-induced shedding
of TIM-1 and TIM-4, however, failed to reach statistical signiﬁcance only
at the lowest concentration of GI (0.2 μM; p = 0.076 andp = 0.072, re-
spectively). These results, however, still support our conclusion that
ADAM10 and ADAM17 are sheddases of TIM-1 and TIM-4.
To further analyzewhether ADAM10 andADAM17were responsible
for ionomycin-induced shedding, we repeated these experiments with
murine embryonic ﬁbroblasts (MEFs) deﬁcient for ADAM10, ADAM17
and ADAM10/ADAM17, which were transiently transfected with
cDNAs coding for AP-TIM-1 or AP-TIM-4. As depicted in Fig. 2D and E,
shedding of AP-TIM-1 and AP-TIM-4 was induced by ionomycin-
treatment in wild-type and ADAM17 deﬁcient MEFs. Ionomycin-
induced shedding of AP-TIM-1 and AP-TIM-4 was reduced in ADAM10
deﬁcient and ADAM10/ADAM17 double deﬁcient but not in ADAM17
deﬁcient MEFs (Fig. 2D and E). PMA-induced shedding of AP-TIM-1 or
AP-TIM-4 was reduced in ADAM17, ADAM10, and ADAM10/ADAM17
double deﬁcient MEFs (Fig. 2D and E). Taken together our data indicate
that TIM-1 and TIM-4 are substrates of the proteases ADAM10 and
ADAM17 and that ionomycin-induced shedding was mediated by
ADAM10 whereas PMA-induced shedding was mediated by ADAM17.3.2. The intracellular domains of TIM-1 and TIM-4 are not involved in
ADAM-mediated shedding
The intracellular domain (ICD) of L-selectin has been shown to be es-
sential for ADAM-mediated shedding [43], whereas the IL-6R ICD was
dispensable for IL-6R cleavage by ADAM17 [44]. Recently, the impor-
tance of the intracellular domain of several EGFR ligands, which are all
substrates of ADAM10 and/or ADAM17, was highlighted for induced
and constitutive shedding [45]. To characterize whether the intracellu-
lar domains of TIM-1 and TIM-4 inﬂuenced ADAM-mediated shedding,
we generated TIM-1 and TIM-4 variants, lacking the intracellular
domains. HEK293 cells were transiently transfected with AP-TIM-1
and AP-TIM-4 cDNAs lacking the coding sequence of the intracellular
domain (AP-TIM-1ΔICD and AP-TIM-4ΔICD). AP-TIM-1ΔICD and AP-
TIM-4ΔICD were expressed on the cell surface of HEK293 cells as mea-
sured by ﬂow cytometry (Fig. 3A). AP-TIM-1ΔICD and AP-TIM-4ΔICD
were efﬁciently shed after ionomycin- and PMA-stimulation as shown
byAP-assays (Fig. 3B). Taken together our data suggest that the intracel-
lular domains of TIM-1 and TIM-4 were not needed for ADAM10- and
ADAM17-mediated shedding.
3.3. Shedding of TIM-1 but not of TIM-4 is abrogated in TIM-deletion variants
which lack amino acids of the membrane-proximal stalk region
The prediction of ADAM cleavage sites is hampered by the fact that
no consensus cleavage sequence exists for ADAM-substrates even
though ADAM10 has a tendency for smaller aliphatic residues at P1′
(Val, Ala) [46]. However, ADAM protease cleavage sites are commonly
located in close vicinity of the plasma membrane [30]. For instance,
the cleavage site of the Interleukin-6 receptor, which is a substrate of
ADAM10 and ADAM17, is located between Gln357 and Asp358, 10
amino acids upstream of the transmembrane region. Deletion of 10
amino acids surrounding the cleavage site completely inhibited PMA-
induced shedding of IL-6R byADAM17 [44] but not byADAM10 [47]. In-
terestingly, Zhang et al. [8] described a non-cleavable TIM-1 variant. De-
letion of 7 amino acids within the mucin stalk domain upstream of the
trans-membrane domain (Δ282-289 FLEHSLL) rendered non-cleav-
able TIM-1 after stimulation with pervanadate, a tyrosine phosphatase
inhibitor [8]. We evaluated the Δ TIM-1 mutant (TIM-1 Δ282-289) in
PMA- and ionomycin-shedding assays (Fig. 4A). As shown in Fig. 4B,
TIM-1Δ282-289 and AP-TIM-1Δ282-289were expressed on the cell sur-
face of transiently transfected HEK293 cells. Ionomycin- and PMA-
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Fig. 2. Induced shedding of AP-TIM-1 and AP-TIM-4 fusion proteins by ADAM10 and ADAM17. (A–B) HEK293 cells, transfected to express AP-TIM-1 or AP-TIM-4 fusion proteins were
stimulated with BzATP (30 min, 500 μM), ionomycin (30 min, 5 μM) or PMA (60 min, 100 nM) in presence or absence of ADAM10-inhibitor GI (3 μM) or combined ADAM10/
ADAM17-inhibitor GW (3 μM). (C–D) MEFs deﬁcient for ADAM10, ADAM17 or for both ADAM10 and ADAM17 and wild-type MEFs expressing AP-TIM-1 or AP-TIM-4 were stimulated
with ionomycin (30 min, 5 μM) and PMA (60 min, 100 nM). The AP-activity was measured and calculated as ratio of the alkaline phosphatase activity in the lysate and the supernatant.
The values represent the mean (±SD) from one representative experiment (n = 3); n.s. = non-signiﬁcant, **p b 0.01, and ***p b 0.001 (unpaired Student's t-test).
280 O. Schweigert et al. / Biochimica et Biophysica Acta 1843 (2014) 275–287induced shedding of TIM-1 Δ282-289 and AP-TIM-1 Δ282-289 was sig-
niﬁcantly reduced as indicated by Western blotting and AP-assays
(Fig. 4C and D). These ﬁndings indicate that the ADAM10- and
ADAM17-protease cleavage site(s) of TIM-1 might be located near the
trans-membrane domain.
For TIM-4, we generated the three stalk deletion variants AP-TIM-4-
Δ304–313, -Δ294–303 and -Δ284–293 each lacking 10 amino acids in
close vicinity of the trans-membrane region (Fig. 5A). As shown in
Fig. 5B and E, all three TIM-4 variantswere expressed on the cell surface
of transiently transfected HEK293 cells. Ionomycin- and PMA-induced
shedding was, however, not abrogated for the TIM-4 or AP-TIM-4 dele-
tion variants as shown by Western blotting and AP-assays (Fig. 5C, D).
All proteins were equally expressed as judged by FACS analysis and
Western blotting (Fig. 5B and D). Our data might point to a reductionof PMA-induced shedding for the TIM-4 variant Δ304–313 (Fig. 5D
and F),which is the deletionmost proximal to themembrane. However,
no reduction of ionomycin-induced sheddingwas observed. By deletion
of membrane-proximal amino acids we generated a TIM-1 variant that
was less efﬁciently shed byADAM10and 17. The same strategy, however,
was only partially successful in generating an un-cleavable TIM-4
protein.
3.4. Shedding of endogenously expressed TIM-1 and TIM-4 is mediated by
ADAM10 and -17
The human kidney carcinoma cell line 769-P endogenously
expresses TIM-1 [48]. Therefore, we analyzed whether shedding of
endogenous TIM-1 from 769-P cells was also mediated by ADAM
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281O. Schweigert et al. / Biochimica et Biophysica Acta 1843 (2014) 275–287proteases. 769-P cells were stimulated with PMA, BzATP or ionomycin
in the absence or presence of the ADAM10-inhibitor GI, the combined
ADAM10/ADAM17-inhibitor GWor left untreated. Soluble TIM-1 protein
released into the cell culture supernatant was visualized by Western
blotting. The ADAM10-inhibitor GI and the combined ADAM10/
ADAM17-inhibitorGWcompletely inhibited the release of endogenously
expressed TIM-1 into the cell culture supernatant after ionomycin- andTim-1 (PE-A) 
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Fig. 6. Shedding of endogenous TIM-1 andTIM-4 in 769-P cells and in vitrodifferentiated humanmacrophages. (A–D) Conﬂuent 769-P cellswere treated as indicated. Lysates and conditioned
mediawere analyzed byWestern blottingusingmouse anti-TIM-1 antibody. (E–F) Conﬂuent769-P cellswere treated as indicatedwith ionomycin (E) and PMA(F) in the presence or absence
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using anti-TIM-4 mAb (isotype control in gray). One representative experiment out of three performed is shown. Fold change was calculated using ImageJ.
283O. Schweigert et al. / Biochimica et Biophysica Acta 1843 (2014) 275–287release of soluble TIM-1 from769-P cells into the cell culture supernatant
(Fig. 6D). Reduced cell surface expression of TIM-1 on 769-P cells after
induction of ADAM-mediated shedding with ionomycin and PMA was
detected by ﬂow cytometry (Fig. 6E and F). These data indicated that
ionomycin and BzATP induced shedding of TIM-1 by ADAM10, whereas
PMA activated shedding of TIM-1 by ADAM17 in 769-P cells.
In vitro differentiated macrophages expressed TIM-4 protein, as
detected by ﬂow cytometry and confocal microscopy (Fig. 6G and
Supplemental Figs. 2 and 3). Most of the TIM-4 protein was, however,Fig. 5. Shedding of TIM-4 was not abrogated by deletion of amino acids within the membrane-
cated deletions in the stalk region. (B and E) Expression of the TIM-4 mutants on the cell surfa
mutants, immunostained for TIM-4 and analyzed by ﬂow cytometry. (C) HEK293 cells were
(100 nM) or 30 min with ionomycin (2.5–5 μM). The AP-activity was measured and calculated
resent themean of three identically treatedwells (±SD); ***p b 0.001 (unpaired Student's t-tes
for 60 min with PMA (100 nM) or 30 min with ionomycin (2.5–5 μM). Lysates and conditionestored in intracellular vesicles. Unfortunately, we were not able to de-
tect endogenous TIM-4 protein by Western blotting or ELISA (data not
shown). Next, we stimulated in vitro differentiated macrophages with
PMA and ionomycin. PMA and ionomycin led to increased cell surface
expression of TIM-4 as detected byﬂow cytometry and confocalmicros-
copy (Supplemental Figs. 2 and 3), whichwas reminiscent of TIM-1 and
TIM-2, which were also reported to be transported to the cell surface
after ionomycin treatment [49]. The transport of intracellularly stored
TIM-4 does not exclude shedding, but prevented the detection of TIM-proximal stalk region. (A) Schematic representation of human TIM-4 protein and the indi-
ce of HEK293 cells. HEK293 cells were transiently transfected with the indicated deletion
transiently transfected with the indicated constructs and treated for 60 min with PMA
as ratio of the alkaline phosphatase activity in the lysate and the supernatant. Values rep-
t). (D) HEK293 cells were transiently transfectedwith indicated constructs and stimulated
d media were analyzed by Western blotting.
284 O. Schweigert et al. / Biochimica et Biophysica Acta 1843 (2014) 275–2874 shedding by ﬂow cytometry. Albeit BzATP stimulation reduced cell
surface expression of TIM-4, this effect was not inhibited by ADAM10
inhibitor GI and combined ADAM10/ADAM17-inhibitor GW
(Supplemental Fig. 2C). Confocal microscopy suggested that BzATP
led to increased internalization of TIM-4 (Supplemental Figs. 2 and 3).
Therefore, BzATP treatment was also not suited to detect shedding of
endogenous TIM-4 on macrophages. Lipopolysaccharide (LPS) was
shown to induce shedding of various substrates by ADAM proteases
[50]. LPS-stimulation of macrophages resulted in a decrease of cell
surface expression of TIM-4, which was almost completely rescued by
the combined ADAM10/ADAM17-inhibitor GW and the broad-spectrum
metalloprotease-inhibitor marimastat but only partially by the ADAM10
inhibitor GI (Fig. 6G). Even thoughwewere not able to detect sTIM-4 pro-
tein directly, our ﬂow cytometry analysis strongly suggested that endog-
enously expressed TIM-4 was shed by ADAM17.
3.5. siRNA knockdown of ADAM10 and ADAM17 completely abrogated
ionomycin- and PMA-induced shedding of TIM-1 from 769-P cells
To independently verify the involvement of ADAM10 and ADAM17
in TIM-1 shedding, 769-P cells were transfected with siRNAs directed
against ADAM10 or ADAM17 or co-transfected with siRNAs targeting
both, ADAM10 and ADAM17. Transfected cells were stimulated with
ionomycin or PMA. Soluble hTIM-1 was detected by Western blotting
and ADAM10 or ADAM17 expression was veriﬁed via ﬂow cytometry.
The expression of ADAM10 and/or ADAM17 was down-regulated
when cells were transfected with siRNAs against ADAM10 and/or
ADAM17 compared to cells transfected with control siRNAs (Fig. 7A).
Down-regulation of ADAM17 expression did not inﬂuence ionomycin-
induced shedding of hTIM-1 from 769-P cells (Fig. 7B). When ADAM10
expression was down-regulated in 769-P cells, ionomycin-induced shed-
ding of TIM-1 was signiﬁcantly reduced (Fig. 7B). For PMA-inducedB
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Fig. 7. Shedding of endogenous TIM-1 following siRNA induced down-regulation of ADAM10 o
769-P cells following siRNA induced down-regulation of ADAM10, and/or ADAM17 via FACS
isotype controls in gray. (B, C) Conditioned media and lysates of 769-P cells following siRNA
(30 min, 5 μM) or PMA (60 min, 100 nM) as indicated were analyzed by Western blotting usishedding, ADAM17 but not ADAM10 down-regulation resulted in abro-
gated TIM-1 shedding (Fig. 7C). These results indicate that ionomycin-
and PMA-induced shedding of TIM-1 in 769-P cells was mediated by
ADAM10 and ADAM17, respectively.
3.6. sTIM-1 and sTIM-4 generated by ectodomain shedding bind
to phosphatidylserine
Next, we analyzed whether shed sTIM-1 and sTIM-4 still retained
their ability to interact with phosphatidylserine (PS) by using PS-
coated plates in a solid-phase enzyme-linked immunoabsorbent assay
(ELISA). HEK293 cells, expressing hTIM-1 or hTIM-4, were stimulated
with ionomycin in the absence or presence of the ADAM10-inhibitor
GI and the combined ADAM10/ADAM17-inhibitor GW. The superna-
tants were collected and applied to PS-coated plates. Bound TIM-1 and
-4 were detected with speciﬁc antibodies. Importantly, shed sTIM-1
and sTIM-4 bound to phosphatidylserine (Fig. 8A and B). Addition of
GI and/or GW suppressed the generation of soluble TIM proteins and
as a consequence reduced binding to PS was observed (Fig. 8A
and B). As expected, no soluble TIM-1 was detectable in the super-
natant of HEK293-hTIM-1 Δ282-289 cells after stimulation with
ionomycin or PMA (Fig. 8C). To exclude unspeciﬁc binding of soluble
TIM-1 and TIM-4 to phosphatidylserine, we veriﬁed that both sTIM-1
and sTIM-4 did not bind to phosphatidylcholine (Fig. 8D and E). Our
results show that shed sTIM-1 and sTIM4 speciﬁcally bind to
phosphatidylserine.
4. Discussion
TIM proteins are associated with various inﬂammatory diseases in-
cluding rheumatoid arthritis, asthma and autoimmunity [3]. TIM-1
was previously described as a renal epithelial cell protein. TIM-1102 103 104 105
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shedding following kidney injury [7,8]. Soluble TIM-1 is a sensitive bio-
marker for acute kidney injury and renal cell carcinoma in humans
[27–29]. Little is known about the physiological consequences of TIM-1
shedding. Investigation of TIM-1 ectodomain shedding including the
identiﬁcation of the involvedmetalloprotease(s)may lead to a better un-
derstanding of the role of TIM-1 in acute injury and in the immune sys-
tem. Cleavage of TIM-1 was inducible by PMA and inhibited by broad
metalloprotease inhibitors BB-94 (Batimastat) and GM6001 (Ilomastat)
[48]. Furthermore Zhang et al. [8] showed that TIM-1 shedding was in-
duced in response to ERKMAPK activation and was accelerated through
activation of the p38 MAP kinase pathway. The metalloprotease
ADAM17mediates shedding of TGF-α after activation of thep38MAP ki-
nase pathway resulting in ADAM17phosphorylation in breast carcinoma
cells [51]. Manymembrane proteins including cytokines, growth factors,
receptors and cell adhesion molecules undergo ectodomain shedding
[30]. For example, the human IL-6 receptor is cleaved from the cell sur-
face by ADAM10 or ADAM17 [32]. Based on these ﬁndings, we investi-
gated whether ADAM proteases are involved in shedding of TIM-1.
Here, we show that treatment with ionomycin, BzATP and PMA led to
shedding of heterogeneously and endogenously-expressed TIM-1, and
that shedding was mediated by ADAM10 and ADAM17. Moreover, we
asked whether the TIM-1 related protein TIM-4 also undergoes
ectodomain shedding and whether ADAM proteases were also involvedsTim-4A B
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Fig. 8. Soluble TIM-1 and TIM-4 bind to phosphatidylserine. (A–E) HEK293 cells expressing
the presence or absence of the ADAM10-inhibitor GI (3 μM) or the combined ADAM
phosphatidylserine (PS)- or (D–E) phosphatidylcholine (PC)-coated plate in an ELISA. Bound
biotinylated anti-TIM-4 antibodies. The values represent the mean (±SD) from one representin this process. As for TIM-1, treatment of cells with ionomycin, BzATP
and PMA led to shedding of TIM-4, which again was mediated by the
proteases ADAM10 and ADAM17. Moreover, using in vitro differentiated
humanmacrophages, our data suggest that endogenous TIM-4 is shed by
ADAM17 after LPS stimulation.
Phosphatidylserine as well as LMIR5 (ligand for leukocyte mono-
immunoglobulin-like receptor 5) [52] and the recently identiﬁed nuclear
orphan receptor NUR77 [53] are ligands of the transmembrane proteins
TIM-1 and TIM-4 [20,21]. TIM-1 is also an entry receptor for Hepatitis A
virus, Marburg virus and EBOLA virus [54]. Targeted activation of
ADAM10 or ADAM17 to cleave the TIM-1 ectodomain might reduce
binding and entry of these viruses via the TIM-1 receptor. Furthermore,
a soluble variant of TIM-1may be used as a therapeutic target to decorate
virus particles and thereby to prevent the interaction of virus particles
with the cellular TIM-1 receptor.
TIM-1 and TIM-4 bind directly to phosphatidylserine and mediate
engulfment of apoptotic cells by phagocytic cells [6,20,21]. It was re-
ported that TIM-1 expression on injured kidney epithelial cells enabled
the ability to recognize and subsequently phagocytize surrounding apo-
ptotic and necrotic cells [55]. The engulfment of apoptotic cells leads to
down-regulation of pro-inﬂammatory responses. Therefore, TIM-1
might modulate immune responses during acute kidney injury [27].
Moreover, TIM-1 and TIM-4 expression conferred murine ﬁbroblasts
with the ability to engulf apoptotic cells [8,9]. In vivo, the blockade ofC
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macrophages to phagocytize apoptotic cells, which led to increased
autoantibody levels [9]. Here, we demonstrate that soluble TIM-1 and
TIM-4 generated by ectodomain shedding bind to phosphatidylserine
but not to phosphatidylcholine. We speculate that this binding might
reduce or prevent the engulfment of apoptotic cells through macro-
phages. Alternatively, soluble TIM-1 and TIM-4 proteinsmight decorate
apoptotic cells and mark them for phagocytosis mediated via homo- or
heterotypic interaction of TIM-proteins orwith other interactionpartners.
5. Conclusions
Our results provide insight into the cell surface regulation of TIM-1
and TIM-4 proteins. We identiﬁed TIM-1 and TIM-4 as novel substrates
for the ADAM proteases ADAM10 and ADAM17. Our in vitro data
showed that the soluble TIM-1 and TIM-4 proteins retained their ability
to bind to phosphatidylserine. The biological relevance of TIM-1 and
TIM-4 ectodomain shedding will need to be studied in more detail.
One possibility is to use un-cleavable TIM proteins in knock-in mice.
Consequently, a speciﬁc deletion in the stalk region of TIM-1 but not
of TIM-4 suppressed ADAM-mediated ectodomain shedding. This variant
might be awell-suited tool to generate un-cleavable TIM-1 knock-inmice
and investigate tumor progression in a renal cancer model.
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